Pharmaceuticals
Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel
SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive ...
2026-06-09 08:21
3220
2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2026-06-08 16:30
3003
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellence in Life Sciences" award, the highest recognition at the 2026 Life Scie...
2026-06-08 16:09
2183
Dong Bang Co Ltd Strengthens Global Competitiveness with Advanced Veterinary Pharmaceuticals
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dong Bang Co Ltd is strengthening its position in the global veterinary pharmaceutical market with high-value products including pet anesthetics and livestock reproductive hormones. Since its establishment in 1983, the company has specialized in m...
2026-06-08 13:00
2065
Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of positive topline results from its Phase II randomized, double-blind, placebo-controlled trial of CG2001 ...
2026-06-08 09:28
3340
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China
SHANGHAI, June 8, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an Asset Pur...
2026-06-08 08:55
5083
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization supporting international execution...
2026-06-08 08:30
2003
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
HONG KONG, June 8, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans, Louisiana), highlighting its differentiated portf...
2026-06-08 08:10
2193
OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
SHANGHAI, June 7, 2026 /PRNewswire/ -- OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") ,announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration (NMPA) to proceed into a confir...
2026-06-08 08:08
2350
Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
SHANGHAI and HONG KONG, June 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...
2026-06-08 08:00
2048
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, today announced that key data from a head-to-head study (SLIMM...
2026-06-08 02:30
2213
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, mor...
2026-06-05 22:00
9044
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, June 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins...
2026-06-05 21:13
10246
China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange
SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and autoimmune diseases in China, listed on the Hong Kong Stock Exchange on June 5, 2026 Beijing time, marking the seventh IPO for Qiming Vent...
2026-06-05 17:10
8206
Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative antibody drug 9MW5211 has received approval from the National Medical Products Adminis...
2026-06-05 11:30
3585
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facil...
2026-06-05 10:45
7121
PharmaBlock's First Peptide GMP Pilot-scale Plant at PharmaBlock Zhejiang Site Now Operational
Next-Generation Peptide CRDMO Solutions Enabled by a Green and Intelligent Platform for Empowering Global Innovative Drug Development NANJING, China, June 4, 2026 /PRNewswire/ -- PharmaBlock Sciences (Stock Code: 300725.SZ) today announced the commissioning of its first peptide pilot-scale GMP p...
2026-06-04 20:21
2700
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly-owned subsidi...
2026-06-04 18:58
3537
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market
* Everest Medicines has obtained exclusive rights for the clinical development and commercialization of Bejescin® (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan regi...
2026-06-04 18:32
3361
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2026-06-04 16:35
4235
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 317 media titles]
2026-06-08 10:16
Visa Partners with OpenAI to Power the Next Generation of AI Commerce
[Picked up by 304 media titles]
2026-06-11 09:30QuettaFlow Technologies Strengthens Global Strategic Alliance with Lead Wealth and Showcases VasEdge at COMPUTEX Taipei 2026
[Picked up by 294 media titles]
2026-06-11 10:00
Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data
[Picked up by 286 media titles]
2026-06-08 09:00
HKC, ANTGAMER, KOORUI Make Strong Debut at COMPUTEX 2026 with World-First Display Innovations
[Picked up by 279 media titles]
2026-06-10 11:13
Most Read
Quantinuum Announces Closing of Upsized Initial Public Offering
2026-06-06 05:08
8245
NYSE Content Update: PointFive Raises $60 Million to Redefine Efficiency
2026-06-08 20:55
7299
SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver
2026-06-06 03:15
6683
